Mode
Text Size
Log in / Sign up
N/A Completed N=163

Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)

Arthritis, Psoriatic
Source: ClinicalTrials.gov NCT00725296 ↗
Enrolled (actual)
163
Serious AEs
3.7%
Results posted
Jul 2011
Primary outcomePrimary: Mean Time Interval Between Infusions During Maintenance Therapy — 57.03; 57.90; 58.59; 56.02 days

Summary

This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Time Interval Between Infusions During Maintenance Therapy
57.03; 57.90; 58.59; 56.02; 56.92; 59.32 —
PRIMARY
Median Time Interval Between Infusions During Maintenance Therapy
56; 56; 56; 56; 56; 56 —
PRIMARY
Average Dose During Induction Therapy and Subsequent Maintenance Therapy
3.92; 3.92; 3.98; 3.96; 3.94; 3.94 —
PRIMARY
Median Dose During Induction Therapy and Subsequent Maintenance Therapy
3.75; 3.75; 3.75; 3.75; 3.75; 3.75 —
PRIMARY
Average Overall Dose of All Infusions Per Participant
4.07 —
PRIMARY
Median Dose of All Infusions Per Participant
3.87 —

Eligibility Criteria

Inclusion Criteria

  • Participants with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drugs.

Exclusion Criteria

  • All according to contraindications in the label especially:
  • Participants with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections.
  • Participants with moderate or severe heart failure (NYHA class III/IV).
  • Participants with a history of hypersensitivity to infliximab or to other murine proteins, or to any of the excipients.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00725296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search